BACKGROUND: Metabolic complications including diabetes mellitus (DM) have been associated with protease inhibitor (PI) therapy. Risk factors for the development of DM are not well-defined. OBJECTIVES: To determine risk factors for the development of new-onset DM in patients initiated on PI therapy. METHODS: A retrospective cohort study was conducted to identify predictors of developing DM in subjects started on PI therapy between January 1997 and January 2003. Diabetes cases were defined as physician documentation of DM in the outpatient medical chart and/or those subjects receiving an antidiabetic agent. Logistic regression was used to examine the relationship between new-onset DM and demographic characteristics, and between new-onset DM and total treatment days with PI therapy. Body mass index could not be entered into the model due to missing height measurements. RESULTS: A total of 496 subjects on PI therapy were included, of which 18 (3.6%) developed DM. The mean age of the subjects was 43.4+/-9.4 years (range 19 to 77) and the mean duration of therapy was 3.0+/-1.9 years (range 0.17 to 7.9). In the multivariate model, older subjects were more likely to develop DM (OR 1.12, 95% CI 1.05 to 1.19; P=0.001). This corresponds to a 12% increased risk of DM for each one-year increase in age. Subjects that weighed more had an increased risk (OR 1.06, 95% CI 1.03 to 1.10; P=0.001), as did those belonging to a non-Aboriginal minority group when compared with Caucasians (OR 6.67, 95% CI 1.56 to 28.41; P=0.01). A longer duration of PI therapy was also significantly associated with developing DM (OR 1.52, 95% CI 1.07 to 2.17; P=0.02). CONCLUSION: A longer duration of PI therapy is associated with an increased risk of developing DM. As with HIV-negative subjects, demographic characteristics such as age, weight and ethnicity were important predictors of developing DM in the present study.
BACKGROUND: Metabolic complications including diabetes mellitus (DM) have been associated with protease inhibitor (PI) therapy. Risk factors for the development of DM are not well-defined. OBJECTIVES: To determine risk factors for the development of new-onset DM in patients initiated on PI therapy. METHODS: A retrospective cohort study was conducted to identify predictors of developing DM in subjects started on PI therapy between January 1997 and January 2003. Diabetes cases were defined as physician documentation of DM in the outpatient medical chart and/or those subjects receiving an antidiabetic agent. Logistic regression was used to examine the relationship between new-onset DM and demographic characteristics, and between new-onset DM and total treatment days with PI therapy. Body mass index could not be entered into the model due to missing height measurements. RESULTS: A total of 496 subjects on PI therapy were included, of which 18 (3.6%) developed DM. The mean age of the subjects was 43.4+/-9.4 years (range 19 to 77) and the mean duration of therapy was 3.0+/-1.9 years (range 0.17 to 7.9). In the multivariate model, older subjects were more likely to develop DM (OR 1.12, 95% CI 1.05 to 1.19; P=0.001). This corresponds to a 12% increased risk of DM for each one-year increase in age. Subjects that weighed more had an increased risk (OR 1.06, 95% CI 1.03 to 1.10; P=0.001), as did those belonging to a non-Aboriginal minority group when compared with Caucasians (OR 6.67, 95% CI 1.56 to 28.41; P=0.01). A longer duration of PI therapy was also significantly associated with developing DM (OR 1.52, 95% CI 1.07 to 2.17; P=0.02). CONCLUSION: A longer duration of PI therapy is associated with an increased risk of developing DM. As with HIV-negative subjects, demographic characteristics such as age, weight and ethnicity were important predictors of developing DM in the present study.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: K E Yarasheski; P Tebas; C Sigmund; S Dagogo-Jack; A Bohrer; J Turk; P A Halban; P E Cryer; W G Powderly Journal: J Acquir Immune Defic Syndr Date: 1999-07-01 Impact factor: 3.731
Authors: Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2002-11-01 Impact factor: 3.731
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: R Walli; O Herfort; G M Michl; T Demant; H Jäger; C Dieterle; J R Bogner; R Landgraf; F D Goebel Journal: AIDS Date: 1998-10-22 Impact factor: 4.177
Authors: Shruti H Mehta; Richard D Moore; David L Thomas; Richard E Chaisson; Mark S Sulkowski Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731
Authors: Allison Longenberger; Jeong Youn Lim; Todd T Brown; Alison Abraham; Frank J Palella; Rita B Effros; Trevor Orchard; Maria Mori Brooks; Lawrence A Kingsley Journal: Future Virol Date: 2011-04 Impact factor: 1.831
Authors: Kathryn A Lindl; David R Marks; Dennis L Kolson; Kelly L Jordan-Sciutto Journal: J Neuroimmune Pharmacol Date: 2010-04-16 Impact factor: 4.147
Authors: Saja S Khuder; Suming Chen; Scott Letendre; Thomas Marcotte; Igor Grant; Donald Franklin; Leah H Rubin; Joseph B Margolick; Lisa P Jacobson; Ned Sacktor; Gypsyamber D'Souza; Valentina Stosor; Jordan E Lake; Giovanna Rapocciolo; Justin C McArthur; Alex M Dickens; Norman J Haughey Journal: Neurology Date: 2019-02-20 Impact factor: 11.800
Authors: Kathy Petoumenos; Signe W Worm; Eric Fontas; Rainer Weber; Stephane De Wit; Mathias Bruyand; Peter Reiss; Wafaa El-Sadr; Antonella D'Arminio Monforte; Nina Friis-Møller; Jens D Lundgren; Matthew G Law Journal: J Int AIDS Soc Date: 2012-10-10 Impact factor: 5.396